Latin America Bladder Bladder Cancer Therapeutics & Diagnostics market - Segmented by type of cancer and geography (2016 - 2021)

  • ID: 3784796
  • Report
  • Region: America, America (exc North), Latin America
  • 96 pages
  • Mordor Intelligence
1 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eli Lilly and Co
  • F Hoffmann-La Roche AG
  • GlaxoSmithKlinePlc
  • MORE
Bladder cancer is a urologic malignancy arising from the epithelial lining of the urinary bladder. It is the ninth most common cancer worldwide in men and women, with the highest recurrence rate. Though there has been development over the past ten years in bladder cancer treatment, a huge void of unmet needs is yet to be filled. The bladder cancer market is expected to grow modestly from USD 25 million in 2015to at a CAGR of 4-7%.

The Latin America bladder cancer therapeutics & diagnostic market is segmented based on:

- Type
- Transitional cell bladder cancer
- Invasive bladder cancer
- Superficial bladder cancer
- Squamous cell bladder cancer
- Other rare types
- Treatment
- Chemotherapy
- Immunotherapy
- Radiation therapy
- Surgery
- Major tests
- Cystoscopy
- Biopsy
- Urinalysis
- Urine Cytology
- Bladder Ultrasound
- Geography
- Argentina
- Brazil

In the Latin America, Uruguay is effected the most by bladder cancer with a death rate of 5.26 per 100,000 and is placed 10th globally. It is followed by Argentina and Brazil with death rates of 2.73 & 2.35 respectively.

Some of the key participants in the industry include Pfizer, GlaxoSmithKline, Sanofi S.A, Roche, Novartis, Eli Lilly and Co, AstraZeneca plc, Bristol-Myers Squibb etc.

Drivers:

- Increasing bladder cancer cases
- Technological developments
- Drug innovations with regard to the bladder cancer
- Government initiatives
- Rise in aging populace
- Advanced health care services
- Upsurge in awareness about bladder diseases and their available therapies in the market
- Increasing health care expenditure

Restraints:

- Rise in the number of patent expirations
- Rise in the use of generic drugs
- Asymptomatic nature of the disease

Please note: As this product is updated at the time of order, dispatch will be 72 hours from the date the order and full payment is received
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eli Lilly and Co
  • F Hoffmann-La Roche AG
  • GlaxoSmithKlinePlc
  • MORE
1.Introduction
1.1 Market Definition
1.2 Research Methodology
1.3 Markets Covered
2. Executive Summary
3. Market Overview
3.1 Market Drivers
3.1.1 Rise in awareness about bladder diseases and their available therapies
3.1.2 Increasing health care expenditure
3.1.3 Innovation in drug development, and subsequent technological advancements
3.2 Market Restraints
3.2.1 Rise in number of patent expirations
3.2.2 Increase in use of generic drugs
3.2.3 Asymptomatic nature of the disease
3.3 Market Opportunitites
3.4 Market Threats
4. Porters Five Force Analysis
4.1 Bargaining Power of suppliers
4.2 Bargaining power of buyers
4.3 Degree of competition
4.4 Threat of substitution
4.5 Threat of new entrants
5. Market Segmentation
5.1 Latin America Bladder Cancer Therapeutics & Diagnostics Market, by Cancer Type
5.1.1 Transitional Cell Bladder Cancer
5.1.2 Superficial Bladder Cancer
5.1.3 Invasive bladder cancer
5.1.4 Squamous cell bladder cancer
5.1.5 Other rare types
5.2 Latin America Bladder Cancer Therapeutics Market
5.2.1 Chemotherapy
5.2.2 Immunotherapy
5.2.3 Radiation therapy
5.2.4 Surgery
5.3 Latin America Bladder Cancer Diagnostics Market
5.3.1 Cystoscopy
5.3.2 Biopsy
5.3.3 Urinalysis
5.3.4 Urine Cytology
5.3.5 Bladder Ultrasound
5.4 Latin America Bladder Cancer Therapeutics & Diagnostics Market, By Region
5.4.1 Argentina
5.4.2 Brazil
6. Competitive Landscape
6.1 Mergers & Acquisitions
6.2 Agreements, Collaborations & Partnerships
6.3 New Product Launches
6.4 Recommendations to new market players
7. Company Profiles
7.1 Novartis International AG
7.2 Pfizer Inc
7.3 GlaxoSmithKline plc
7.4 Sanofi S.A
7.5 Eli Lilly and Co
7.6 AstraZeneca plc
7.7 Bristol-Myers Squibb
7.8 F. Hoffmann-La Roche AG
7.9 Celgene Corporation
8. Appendix
8.1. Abbreviations
8.2. Sources
8.3. Bibliography
8.4. Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Novartis International AG
Pfizer Inc.
GlaxoSmithKlinePlc
Sanofi SA
Eli Lilly and Co
AstraZeneca Plc
Bristol-Myers Squibb
F Hoffmann-La Roche AG
Celgene Corporation
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll